

the biggest difference—from the smiling faces at the information desks to the friendly escorts who help patients find their way from one department to another. Auxiliary volunteers are present wherever patients or their families need support—from the Infusion Suite to the Emergency Department. They offer art therapy, play music, and deliver flowers and books.

**Bingo:** Volunteers also run a weekly bingo game—piped in to every patient room over closed-circuit TV. That effort alone entails assembling 250 packets of game supplies, emceeding the game itself, and then delivering prizes to the winners.

One of the most unusual volunteer jobs at DHMC was conceived and filled by chemistry professor John Amsden when he retired from Dartmouth. He set up shop as a Medicare consultant for patients when the program began in 1966. His model was later promulgated to hospitals nationwide by the federal agency that oversees Medicare.

Among the Auxiliary's newer programs are two that require special training of volunteers: Befriend, which offers peer support to patients with breast cancer, and No One Alone, which serves patients in the palliative-care program.

**Work:** “We now take for granted what we have in DHMC,” says Blough. “I’d like people to realize the long period of development.” She knows there’s no magic wand—and that the success of the next 75 years depends on today’s hard work.

ROSEMARY LUNARDINI



**DHMC's Auxiliary was born of a tradition called Donation Day, when local farmers dropped off harvest surplus, which was fed to patients through the winter. On this early Donation Day, the Hospital lawn is piled with boxes and bushels of produce.**



**In 1934, the Auxiliary purchased a book cart, which volunteers wheeled around to patients in their rooms.**



**In 1968, the Auxiliary opened the Pink Smock Gift Shop. Here, Mary Burke and Betty Jordan ring up an early sale.**



**Today, the Auxiliary raises over \$300,000 a year and fields 500-some volunteers. Barbara Blough, right, the organization's current president, and the late Foster Blough, left, were named Quarter-Century Volunteer Honorees earlier this year.**

## THEN & NOW

**A reminder of the pace of change, and of timeless truths, from the Fall 1977 issue of this magazine:**

Dr. Maurice Costin, DMS Class of 1940, shared some recollections of Dr. William Bodwell, Class of 1909. Their paths had crossed “when Dr. Costin set up his practice in Framingham [Mass.] in 1948 and over the years they exchanged stories of their days in Hanover. Dr. Costin [wrote in 1977] that ‘Dr. Bodwell . . . used to have several jobs while working his way through Dartmouth. They included barbering, bartending, washing dishes, waiting on tables, helping Dr. Gilman Frost deliver calves on his farm, and taking care of Professor Emory’s horses.’”



2

Number of students in the DMS Class of 2009 who grew up on a farm

MARK WASHBURN

THEN & NOW

A reminder of the pace of change, and of timeless truths, from *The Journal of William Tully—a diary kept during 1808-09 by a Dartmouth medical student.*

On November 29, 1808, Tully wrote in his diary about a lecture by DMS founder Dr. Nathan Smith. Smith “mentioned the importance of anatomy and physiology,” called “the benefits of chemistry . . . inexhaustible,” and said “botany is likewise of immense importance,” Tully wrote. And, he went on, Smith told his students such knowledge “is also essential to private gentlemen,” not just those studying medicine, because “a man who does not understand [science] appears like an ass in everything.”



4

Number of science courses required in 2008 to earn a bachelor of arts from Dartmouth College

## A blue-light special—in the brain

Each year, about 20,000 Americans find out that they have a cancer that originated in their brain. For most of them, the outlook is grim.

**Rapid:** High-grade brain tumors—known as gliomas—progress rapidly and usually result in death within a year. Even less-malignant gliomas can cause death or disability, and they sometimes progress into high-grade tumors.

Treatment typically includes surgical removal of the tumor. The more of it the surgeon can remove, the longer the patient is likely to survive. Take out too little, and survival time goes down. But take too aggressive an approach, and the result can be a loss of normal tissue—and thus brain function.

It would help, says Dr. David Roberts, chief of neurosurgery at DHMC, if it were easier to tell where the tumor ends and normal brain tissue begins. “It’s the kind of thing we’ve often had on our wish list,” Roberts says. “Wouldn’t it be nice if everything were color coded?” Thanks to research he is conducting with Dr. Keith Paulsen, a professor at Dartmouth’s Thayer School of Engineering, surgeons may soon get their wish.

**Team:** Roberts and Paulsen have collaborated for years on developing cutting-edge technologies to improve surgical outcomes. “I work with Keith more closely than I do with most of my medical colleagues,” says Rob-



erts. “We’re part of the same team.” In 2007, they began their current project, a five-year clinical trial designed to improve the resection, or surgical removal, of gliomas by using fluorescence to highlight tumor tissue.

The trial takes advantage of a reaction that occurs between tumor cells and a chemical called 5-amino levulinic acid (5-ALA). The chemical causes tumor tissue to fluoresce under blue light, but it does not react with normal tissue.

**Glowing:** Three hours before their operation, patients enrolled in the study drink a glass of water containing 5-ALA. Then during surgery, Roberts can take advantage of the effect by flipping a switch on the operating microscope to change the light shining on the patient’s brain from white to blue. The result is a pink, glowing tumor. “It looks like lava,” says Roberts. When Paulsen first saw the effect in the operating room, he was “flabbergasted.”

**When Paulsen first saw the effect in the OR, he was “flabbergasted.”**

Six patients have undergone surgery using 5-ALA so far, and 18 more will be enrolled during the initial stage of the trial. During this phase, Roberts and Paulsen hope to gain a better understanding of how the fluorescence works and how best to take advantage of it. For one thing, Paulsen says, he’d like to develop a means of quantifying the brightness of the fluorescence, which would give surgeons even more information about whether certain tissues are



Above is the same brain tumor—first as seen through a regular operating microscope (top) and then as seen under a blue light that causes the tumor to fluoresce and turn pink (bottom).

part of the tumor. “I think it’s only scratching the surface of what’s possible,” he says.

**Stage:** Midway through the five-year study, a second phase will pit the procedure against tumor resections done without fluorescence. This randomized stage of the trial will address important questions—such as whether using fluorescence leads to more complete resections and longer survival times.

Roberts and Paulsen have a lot of work still ahead of them, but they’re clearly impressed by the technology. “It’s like looking through a telescope for the first time,” says Roberts.

AMOS ESTY

